Skip to content
lifestyle.utv.ie
Animals
Auto
Beauty & Style
Business News
Entertainment
Food
Health
Home & Family
Podcasts
Tech
Travel
Author:
Acurx Pharmaceuticals, Inc.
Acurx Pharmaceuticals Receives FDA Conditional Acceptance and USPTO Trademark Allowance for the Company’s Brand Name for Ibezapolstat
August 17, 2026
Acurx Pharmaceuticals, Inc. Reports Second Quarter 2026 results and provides business update
August 14, 2026
Japan and Mexico Patent Offices Both Grant Acurx Pharmaceuticals New Patents for DNA Polymerase IIIC Inhibitor Antibiotics
August 12, 2026
Acurx Announces Scientific Partnership with Leiden University Medical Center to Advance Development of Acurx’s DNA Polymerase IIIC Inhibitor Antibiotics
August 10, 2026
FDA Provides Further Regulatory Guidance to Acurx Pharmaceuticals for the Ibezapolstat Clinical Development Program, Including the Potential for a Single-Phase 3-Trial Registration Plan and a Trial Design to Support Both Treatment and Reduction of Recurrence of C. difficile Infection
August 3, 2026
Acurx Pharmaceuticals Announces Presentation of Results from Leiden University Medical Center Public-Private Partnership for Its DNA pol IIIC Inhibitors at the Leiden Early Drug Discovery & Development (LED3) Scientific Conference
June 16, 2026
Acurx Pharmaceuticals, Inc. Reports First Quarter 2026 results and Provides Business Update
May 12, 2026
Acurx Announces Scientific Poster Presentation of its DNA pol IIIC Inhibitors’ Microbiome Evaluation at ESCMID Global 2026
May 5, 2026
Acurx Pharmaceuticals to Present at the Alliance Global Partners (A.G.P) Healthcare Company Showcase
May 4, 2026
Acurx Pharmaceuticals to Discuss First Quarter 2026 Financial Results on May 12, 2026 Conference Call and Provide Business Update
May 3, 2026
1
2
Next Page
→